BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6994787)

  • 1. Effect of guanfacine on blood pressure and renin activity in hypertensive patients.
    Rosenthal J
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):91S-96S. PubMed ID: 6994787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
    Rosenthal J; Jäger H
    MMW Munch Med Wochenschr; 1980 Jan; 122(4):137-40. PubMed ID: 6767938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.
    Manhem P; Hökfelt B
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):109S-114S. PubMed ID: 6994763
    [No Abstract]   [Full Text] [Related]  

  • 4. Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity.
    Schoeppe W; Brecht HM
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):97S-101S. PubMed ID: 6994788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG; Bloxham CA; Walker JM
    Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An ambulatory trial of guanfacine.
    Mann S; Millar Craig MW; Melville DI; Cashman PM; Raftery EB
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):103S-107S. PubMed ID: 6994762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of long-term treatment of essential hypertension with guanfacine.
    Higuchi M; Overlack A; Stumpe KO
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):61S-64S. PubMed ID: 6994780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
    Rosenthal JH
    Am J Cardiol; 1986 Mar; 57(9):22E-26E. PubMed ID: 3513526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new centrally action antihypertensive agent guanfacine (BS 100-141).
    Dubach UC; Huwyler R; Radielovic P; Singeisen M
    Arzneimittelforschung; 1977; 27(3):674-6. PubMed ID: 326262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical dose-response studies with guanfacine (BS 100-141), a new antihypertensive agent.
    MacCarthy P; Isaac P; Frost G; Freeman A; Stokes G
    Clin Exp Pharmacol Physiol; 1978; 5(2):187-90. PubMed ID: 348364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of two antihypertensive agents: guanfacine and guanethidine.
    Szám I; Kállay K
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):85S-87S. PubMed ID: 6994786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new antihypertensive agent used in a clinical setting].
    Wetzels E; Raschig A; Kaiser HJ
    Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between blood pressure, heart rate and plasma epinephrine, norepinephrine, angiotensin II concentrations, plasma renin activity during chronic guanfacine therapy in patients with essential arterial hypertension.
    Collart F; Staroukine M; Verniory A
    Acta Cardiol; 1985; 40(3):269-76. PubMed ID: 3895792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
    Jerie P; Lasance A
    Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 17. Haemodynamics in hypertensive patients before and during guanfacine treatment.
    Schäfer N; Rauh J; Rosenthal J
    Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):133S-135S. PubMed ID: 6994767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 19. [Controlled doubleblind study on dose-effect relationship of guanfacine a long-acting hypotensive guanidine derivative (author's transl)].
    Magometschnigg D; Bonelli J; Hitzenberger G; Kaik G
    Arzneimittelforschung; 1980; 30(6):1005-7. PubMed ID: 6998487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of guanfacine on growth hormone, prolactin, renin, lipoproteins and glucose in essential hypertension.
    Hauger-Klevene JH; Balossi EC; Scornavacchi JC
    Am J Cardiol; 1986 Mar; 57(9):27E-31E. PubMed ID: 3513527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.